KEYWORDS: Patient-derived organoids urothelial cancer bladder cancer drug response prediction drug discovery antibody drug conjugates immune checkpoint inhibitors 1. State-of-the-art Bladder cancer (BC) displays extensive inter- and intratumoral heterogeneity at histologic, molecular, and microenvironmental levels.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile